Dr. Reddy's Biologics Plant Receives US FDA Form 483 With Seven Observations

Q1 FY27 Consolidated Results YoY: Revenue at 8071 Cr vs 8545 Cr, down 5.6%. EBITDA at 1009 Cr vs 2278 Cr, down 55.7%; includes 240 Cr semaglutide inventory provision. EBITDA Margin at 12.5% vs 26.7%, contraction of 1420bps. PAT at 444 Cr vs 1418 Cr, down 68.7%. Global Generics revenue declined 5% on lenalidomide drop, while base business delivered strong double-digit growth; PSAI gross profit fell sharply. Received a USFDA Form 483 with 7 observations at the Bachupally biologics facility.